nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR2A—chronic obstructive pulmonary disease	0.544	1	CbGaD
Lurasidone—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0404	0.282	CbGbCtD
Lurasidone—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0273	0.19	CbGbCtD
Lurasidone—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.026	0.182	CbGbCtD
Lurasidone—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0232	0.162	CbGbCtD
Lurasidone—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.0179	0.321	CbGeAlD
Lurasidone—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0136	0.0949	CbGbCtD
Lurasidone—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0128	0.0897	CbGbCtD
Lurasidone—HTR7—pulmonary artery—chronic obstructive pulmonary disease	0.0104	0.187	CbGeAlD
Lurasidone—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.0065	0.116	CbGeAlD
Lurasidone—Ziprasidone—SLC6A4—chronic obstructive pulmonary disease	0.00177	0.373	CrCbGaD
Lurasidone—HTR7—respiratory system—chronic obstructive pulmonary disease	0.00175	0.0314	CbGeAlD
Lurasidone—DRD2—respiratory system—chronic obstructive pulmonary disease	0.00166	0.0297	CbGeAlD
Lurasidone—Ziprasidone—CYP1A2—chronic obstructive pulmonary disease	0.00161	0.34	CrCbGaD
Lurasidone—HTR7—connective tissue—chronic obstructive pulmonary disease	0.00154	0.0276	CbGeAlD
Lurasidone—HTR7—smooth muscle tissue—chronic obstructive pulmonary disease	0.00141	0.0253	CbGeAlD
Lurasidone—Ziprasidone—HTR2A—chronic obstructive pulmonary disease	0.00136	0.287	CrCbGaD
Lurasidone—ADRA2C—bronchus—chronic obstructive pulmonary disease	0.00133	0.0238	CbGeAlD
Lurasidone—HTR7—trachea—chronic obstructive pulmonary disease	0.0013	0.0232	CbGeAlD
Lurasidone—ADRA2C—trachea—chronic obstructive pulmonary disease	0.00119	0.0213	CbGeAlD
Lurasidone—ADRA2A—connective tissue—chronic obstructive pulmonary disease	0.00113	0.0203	CbGeAlD
Lurasidone—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.00109	0.0196	CbGeAlD
Lurasidone—ADRA2A—bronchus—chronic obstructive pulmonary disease	0.00106	0.019	CbGeAlD
Lurasidone—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000963	0.0172	CbGeAlD
Lurasidone—ADRA2A—trachea—chronic obstructive pulmonary disease	0.000951	0.017	CbGeAlD
Lurasidone—HTR7—lung—chronic obstructive pulmonary disease	0.000931	0.0167	CbGeAlD
Lurasidone—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000881	0.0158	CbGeAlD
Lurasidone—DRD2—lung—chronic obstructive pulmonary disease	0.000881	0.0158	CbGeAlD
Lurasidone—ADRA2C—lung—chronic obstructive pulmonary disease	0.000856	0.0153	CbGeAlD
Lurasidone—HTR2A—trachea—chronic obstructive pulmonary disease	0.000808	0.0145	CbGeAlD
Lurasidone—ADRA2A—lung—chronic obstructive pulmonary disease	0.000683	0.0122	CbGeAlD
Lurasidone—HTR2A—lung—chronic obstructive pulmonary disease	0.000581	0.0104	CbGeAlD
Lurasidone—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.00048	0.00248	CcSEcCtD
Lurasidone—Amenorrhoea—Prednisone—chronic obstructive pulmonary disease	0.000479	0.00247	CcSEcCtD
Lurasidone—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000478	0.00247	CcSEcCtD
Lurasidone—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000474	0.00245	CcSEcCtD
Lurasidone—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000474	0.00244	CcSEcCtD
Lurasidone—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000471	0.00243	CcSEcCtD
Lurasidone—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00047	0.00243	CcSEcCtD
Lurasidone—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00047	0.00243	CcSEcCtD
Lurasidone—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00047	0.00242	CcSEcCtD
Lurasidone—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000468	0.00242	CcSEcCtD
Lurasidone—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000467	0.00241	CcSEcCtD
Lurasidone—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000467	0.00241	CcSEcCtD
Lurasidone—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000465	0.0024	CcSEcCtD
Lurasidone—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000464	0.00239	CcSEcCtD
Lurasidone—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000461	0.00238	CcSEcCtD
Lurasidone—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000461	0.00238	CcSEcCtD
Lurasidone—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00046	0.00237	CcSEcCtD
Lurasidone—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000459	0.00237	CcSEcCtD
Lurasidone—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000453	0.00234	CcSEcCtD
Lurasidone—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000453	0.00234	CcSEcCtD
Lurasidone—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000452	0.00233	CcSEcCtD
Lurasidone—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000452	0.00233	CcSEcCtD
Lurasidone—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000449	0.00232	CcSEcCtD
Lurasidone—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000449	0.00232	CcSEcCtD
Lurasidone—Increased appetite—Prednisolone—chronic obstructive pulmonary disease	0.000447	0.00231	CcSEcCtD
Lurasidone—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000447	0.00231	CcSEcCtD
Lurasidone—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000444	0.00229	CcSEcCtD
Lurasidone—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000441	0.00228	CcSEcCtD
Lurasidone—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000441	0.00228	CcSEcCtD
Lurasidone—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00044	0.00227	CcSEcCtD
Lurasidone—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000438	0.00226	CcSEcCtD
Lurasidone—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000438	0.00226	CcSEcCtD
Lurasidone—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000436	0.00225	CcSEcCtD
Lurasidone—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000435	0.00225	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000431	0.00222	CcSEcCtD
Lurasidone—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00043	0.00222	CcSEcCtD
Lurasidone—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00043	0.00222	CcSEcCtD
Lurasidone—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000429	0.00221	CcSEcCtD
Lurasidone—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000428	0.00221	CcSEcCtD
Lurasidone—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000427	0.00221	CcSEcCtD
Lurasidone—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000427	0.00221	CcSEcCtD
Lurasidone—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000427	0.0022	CcSEcCtD
Lurasidone—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000424	0.00219	CcSEcCtD
Lurasidone—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000422	0.00218	CcSEcCtD
Lurasidone—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000422	0.00218	CcSEcCtD
Lurasidone—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000421	0.00217	CcSEcCtD
Lurasidone—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.00042	0.00217	CcSEcCtD
Lurasidone—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000418	0.00216	CcSEcCtD
Lurasidone—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000416	0.00215	CcSEcCtD
Lurasidone—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000414	0.00213	CcSEcCtD
Lurasidone—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00041	0.00212	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000408	0.00211	CcSEcCtD
Lurasidone—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000406	0.00209	CcSEcCtD
Lurasidone—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000404	0.00208	CcSEcCtD
Lurasidone—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000404	0.00208	CcSEcCtD
Lurasidone—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000403	0.00208	CcSEcCtD
Lurasidone—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000398	0.00205	CcSEcCtD
Lurasidone—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000398	0.00205	CcSEcCtD
Lurasidone—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000398	0.00205	CcSEcCtD
Lurasidone—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000397	0.00205	CcSEcCtD
Lurasidone—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000397	0.00205	CcSEcCtD
Lurasidone—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000397	0.00205	CcSEcCtD
Lurasidone—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000397	0.00205	CcSEcCtD
Lurasidone—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000396	0.00205	CcSEcCtD
Lurasidone—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000396	0.00204	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000395	0.00204	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000395	0.00204	CcSEcCtD
Lurasidone—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00039	0.00201	CcSEcCtD
Lurasidone—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000389	0.00201	CcSEcCtD
Lurasidone—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000389	0.00201	CcSEcCtD
Lurasidone—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000388	0.00201	CcSEcCtD
Lurasidone—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000388	0.002	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000387	0.002	CcSEcCtD
Lurasidone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000387	0.002	CcSEcCtD
Lurasidone—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000381	0.00197	CcSEcCtD
Lurasidone—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000379	0.00196	CcSEcCtD
Lurasidone—Infection—Formoterol—chronic obstructive pulmonary disease	0.000379	0.00196	CcSEcCtD
Lurasidone—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000376	0.00194	CcSEcCtD
Lurasidone—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000374	0.00193	CcSEcCtD
Lurasidone—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000374	0.00193	CcSEcCtD
Lurasidone—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000374	0.00193	CcSEcCtD
Lurasidone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000374	0.00193	CcSEcCtD
Lurasidone—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000372	0.00192	CcSEcCtD
Lurasidone—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000372	0.00192	CcSEcCtD
Lurasidone—Infection—Montelukast—chronic obstructive pulmonary disease	0.000371	0.00192	CcSEcCtD
Lurasidone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000371	0.00191	CcSEcCtD
Lurasidone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000371	0.00191	CcSEcCtD
Lurasidone—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000368	0.0019	CcSEcCtD
Lurasidone—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000366	0.00189	CcSEcCtD
Lurasidone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000363	0.00187	CcSEcCtD
Lurasidone—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000358	0.00185	CcSEcCtD
Lurasidone—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000357	0.00184	CcSEcCtD
Lurasidone—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000357	0.00184	CcSEcCtD
Lurasidone—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000355	0.00183	CcSEcCtD
Lurasidone—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.00183	CcSEcCtD
Lurasidone—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000353	0.00182	CcSEcCtD
Lurasidone—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000352	0.00182	CcSEcCtD
Lurasidone—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000351	0.00181	CcSEcCtD
Lurasidone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00035	0.00181	CcSEcCtD
Lurasidone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.0018	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000348	0.00179	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000348	0.00179	CcSEcCtD
Lurasidone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00178	CcSEcCtD
Lurasidone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00178	CcSEcCtD
Lurasidone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000343	0.00177	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00034	0.00176	CcSEcCtD
Lurasidone—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00176	CcSEcCtD
Lurasidone—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00176	CcSEcCtD
Lurasidone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000339	0.00175	CcSEcCtD
Lurasidone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.00175	CcSEcCtD
Lurasidone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000338	0.00174	CcSEcCtD
Lurasidone—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000337	0.00174	CcSEcCtD
Lurasidone—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000336	0.00173	CcSEcCtD
Lurasidone—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000336	0.00173	CcSEcCtD
Lurasidone—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000334	0.00173	CcSEcCtD
Lurasidone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000332	0.00171	CcSEcCtD
Lurasidone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000331	0.00171	CcSEcCtD
Lurasidone—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000331	0.00171	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000329	0.0017	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000329	0.0017	CcSEcCtD
Lurasidone—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000329	0.0017	CcSEcCtD
Lurasidone—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000329	0.0017	CcSEcCtD
Lurasidone—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000329	0.0017	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00169	CcSEcCtD
Lurasidone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00168	CcSEcCtD
Lurasidone—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000325	0.00168	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000323	0.00167	CcSEcCtD
Lurasidone—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000322	0.00166	CcSEcCtD
Lurasidone—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00166	CcSEcCtD
Lurasidone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.00165	CcSEcCtD
Lurasidone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000319	0.00165	CcSEcCtD
Lurasidone—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000317	0.00164	CcSEcCtD
Lurasidone—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000316	0.00163	CcSEcCtD
Lurasidone—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000316	0.00163	CcSEcCtD
Lurasidone—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000313	0.00162	CcSEcCtD
Lurasidone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000313	0.00161	CcSEcCtD
Lurasidone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000312	0.00161	CcSEcCtD
Lurasidone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000312	0.00161	CcSEcCtD
Lurasidone—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000312	0.00161	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000311	0.00161	CcSEcCtD
Lurasidone—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000311	0.0016	CcSEcCtD
Lurasidone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000306	0.00158	CcSEcCtD
Lurasidone—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000305	0.00158	CcSEcCtD
Lurasidone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000302	0.00156	CcSEcCtD
Lurasidone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000302	0.00156	CcSEcCtD
Lurasidone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000301	0.00155	CcSEcCtD
Lurasidone—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000298	0.00154	CcSEcCtD
Lurasidone—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000298	0.00154	CcSEcCtD
Lurasidone—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000298	0.00154	CcSEcCtD
Lurasidone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000298	0.00154	CcSEcCtD
Lurasidone—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000296	0.00153	CcSEcCtD
Lurasidone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000295	0.00153	CcSEcCtD
Lurasidone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000295	0.00152	CcSEcCtD
Lurasidone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000285	0.00147	CcSEcCtD
Lurasidone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000281	0.00145	CcSEcCtD
Lurasidone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00141	CcSEcCtD
Lurasidone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00141	CcSEcCtD
Lurasidone—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00139	CcSEcCtD
Lurasidone—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00139	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000269	0.00139	CcSEcCtD
Lurasidone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00138	CcSEcCtD
Lurasidone—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00136	CcSEcCtD
Lurasidone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000261	0.00135	CcSEcCtD
Lurasidone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000261	0.00135	CcSEcCtD
Lurasidone—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.00026	0.00134	CcSEcCtD
Lurasidone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00133	CcSEcCtD
Lurasidone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000256	0.00132	CcSEcCtD
Lurasidone—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00132	CcSEcCtD
Lurasidone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000252	0.0013	CcSEcCtD
Lurasidone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000252	0.0013	CcSEcCtD
Lurasidone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000247	0.00128	CcSEcCtD
Lurasidone—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000247	0.00127	CcSEcCtD
Lurasidone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000246	0.00127	CcSEcCtD
Lurasidone—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000243	0.00126	CcSEcCtD
Lurasidone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000243	0.00125	CcSEcCtD
Lurasidone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000243	0.00125	CcSEcCtD
Lurasidone—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000241	0.00124	CcSEcCtD
Lurasidone—Rash—Formoterol—chronic obstructive pulmonary disease	0.000241	0.00124	CcSEcCtD
Lurasidone—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00124	CcSEcCtD
Lurasidone—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00124	CcSEcCtD
Lurasidone—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.00024	0.00124	CcSEcCtD
Lurasidone—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000239	0.00123	CcSEcCtD
Lurasidone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000238	0.00123	CcSEcCtD
Lurasidone—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000238	0.00123	CcSEcCtD
Lurasidone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000238	0.00123	CcSEcCtD
Lurasidone—Rash—Montelukast—chronic obstructive pulmonary disease	0.000236	0.00122	CcSEcCtD
Lurasidone—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000235	0.00122	CcSEcCtD
Lurasidone—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000231	0.00119	CcSEcCtD
Lurasidone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.00118	CcSEcCtD
Lurasidone—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000228	0.00118	CcSEcCtD
Lurasidone—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.00117	CcSEcCtD
Lurasidone—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.00117	CcSEcCtD
Lurasidone—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.00117	CcSEcCtD
Lurasidone—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.00117	CcSEcCtD
Lurasidone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00117	CcSEcCtD
Lurasidone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00117	CcSEcCtD
Lurasidone—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000223	0.00115	CcSEcCtD
Lurasidone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00115	CcSEcCtD
Lurasidone—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.00113	CcSEcCtD
Lurasidone—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.00113	CcSEcCtD
Lurasidone—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000215	0.00111	CcSEcCtD
Lurasidone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.0011	CcSEcCtD
Lurasidone—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000208	0.00107	CcSEcCtD
Lurasidone—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000203	0.00105	CcSEcCtD
Lurasidone—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000202	0.00104	CcSEcCtD
Lurasidone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.0002	0.00103	CcSEcCtD
Lurasidone—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000197	0.00102	CcSEcCtD
Lurasidone—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000192	0.00099	CcSEcCtD
Lurasidone—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000189	0.000975	CcSEcCtD
Lurasidone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.000965	CcSEcCtD
Lurasidone—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000956	CcSEcCtD
Lurasidone—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000184	0.00095	CcSEcCtD
Lurasidone—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000895	CcSEcCtD
Lurasidone—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.00017	0.000878	CcSEcCtD
Lurasidone—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000873	CcSEcCtD
Lurasidone—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000868	CcSEcCtD
Lurasidone—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000856	CcSEcCtD
Lurasidone—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000853	CcSEcCtD
Lurasidone—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000852	CcSEcCtD
Lurasidone—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000162	0.000835	CcSEcCtD
Lurasidone—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000159	0.000823	CcSEcCtD
Lurasidone—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00082	CcSEcCtD
Lurasidone—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000157	0.000809	CcSEcCtD
Lurasidone—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000806	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000803	CcSEcCtD
Lurasidone—Infection—Prednisone—chronic obstructive pulmonary disease	0.000149	0.00077	CcSEcCtD
Lurasidone—Shock—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000763	CcSEcCtD
Lurasidone—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000147	0.00076	CcSEcCtD
Lurasidone—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000756	CcSEcCtD
Lurasidone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000146	0.000753	CcSEcCtD
Lurasidone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000749	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000706	CcSEcCtD
Lurasidone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.000705	CcSEcCtD
Lurasidone—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000701	CcSEcCtD
Lurasidone—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000682	CcSEcCtD
Lurasidone—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000674	CcSEcCtD
Lurasidone—Rash—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000673	CcSEcCtD
Lurasidone—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000672	CcSEcCtD
Lurasidone—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000668	CcSEcCtD
Lurasidone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000634	CcSEcCtD
Lurasidone—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.000634	CcSEcCtD
Lurasidone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000613	CcSEcCtD
Lurasidone—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000556	CcSEcCtD
Lurasidone—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000548	CcSEcCtD
Lurasidone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000103	0.00053	CcSEcCtD
Lurasidone—Dizziness—Prednisone—chronic obstructive pulmonary disease	9.93e-05	0.000513	CcSEcCtD
Lurasidone—Vomiting—Prednisone—chronic obstructive pulmonary disease	9.55e-05	0.000493	CcSEcCtD
Lurasidone—Rash—Prednisone—chronic obstructive pulmonary disease	9.47e-05	0.000489	CcSEcCtD
Lurasidone—Dermatitis—Prednisone—chronic obstructive pulmonary disease	9.46e-05	0.000488	CcSEcCtD
Lurasidone—Nausea—Prednisone—chronic obstructive pulmonary disease	8.92e-05	0.00046	CcSEcCtD
Lurasidone—DRD2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.83e-05	0.000833	CbGpPWpGaD
Lurasidone—HTR7—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	4.82e-05	0.000832	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.81e-05	0.00083	CbGpPWpGaD
Lurasidone—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.8e-05	0.000828	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.79e-05	0.000827	CbGpPWpGaD
Lurasidone—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.73e-05	0.000817	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.73e-05	0.000816	CbGpPWpGaD
Lurasidone—HTR2A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	4.68e-05	0.000808	CbGpPWpGaD
Lurasidone—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	4.63e-05	0.000799	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.59e-05	0.000792	CbGpPWpGaD
Lurasidone—HTR7—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.58e-05	0.000791	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—MMP1—chronic obstructive pulmonary disease	4.57e-05	0.000789	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.52e-05	0.000781	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—PLAU—chronic obstructive pulmonary disease	4.49e-05	0.000774	CbGpPWpGaD
Lurasidone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.46e-05	0.00077	CbGpPWpGaD
Lurasidone—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.41e-05	0.000761	CbGpPWpGaD
Lurasidone—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.41e-05	0.000761	CbGpPWpGaD
Lurasidone—HTR1A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4.37e-05	0.000755	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.37e-05	0.000755	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.35e-05	0.000751	CbGpPWpGaD
Lurasidone—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.35e-05	0.000751	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.32e-05	0.000746	CbGpPWpGaD
Lurasidone—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.31e-05	0.000745	CbGpPWpGaD
Lurasidone—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	4.25e-05	0.000734	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.22e-05	0.000728	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.19e-05	0.000724	CbGpPWpGaD
Lurasidone—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.18e-05	0.000722	CbGpPWpGaD
Lurasidone—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.12e-05	0.000712	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—NOS2—chronic obstructive pulmonary disease	4.12e-05	0.000711	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.08e-05	0.000704	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.97e-05	0.000686	CbGpPWpGaD
Lurasidone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.92e-05	0.000676	CbGpPWpGaD
Lurasidone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.85e-05	0.000665	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.84e-05	0.000664	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.81e-05	0.000657	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	3.8e-05	0.000657	CbGpPWpGaD
Lurasidone—HTR2A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.78e-05	0.000652	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3.76e-05	0.000649	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	3.71e-05	0.000641	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.7e-05	0.000639	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	3.64e-05	0.000629	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.64e-05	0.000629	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.61e-05	0.000623	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.55e-05	0.000613	CbGpPWpGaD
Lurasidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.5e-05	0.000605	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.49e-05	0.000603	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.49e-05	0.000602	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	3.47e-05	0.000599	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—ALB—chronic obstructive pulmonary disease	3.46e-05	0.000598	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	3.45e-05	0.000596	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.44e-05	0.000593	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.43e-05	0.000593	CbGpPWpGaD
Lurasidone—DRD2—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	3.42e-05	0.000591	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.42e-05	0.000591	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.4e-05	0.000587	CbGpPWpGaD
Lurasidone—HTR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.4e-05	0.000586	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GCLC—chronic obstructive pulmonary disease	3.38e-05	0.000584	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	3.36e-05	0.000581	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.35e-05	0.000579	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	3.35e-05	0.000578	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.31e-05	0.000572	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—NOS3—chronic obstructive pulmonary disease	3.31e-05	0.000572	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.29e-05	0.000568	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.29e-05	0.000567	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.22e-05	0.000557	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.17e-05	0.000547	CbGpPWpGaD
Lurasidone—DRD2—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	3.13e-05	0.000541	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.12e-05	0.000539	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.12e-05	0.000539	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.12e-05	0.000538	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.12e-05	0.000538	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.12e-05	0.000538	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.11e-05	0.000536	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CTGF—chronic obstructive pulmonary disease	3.09e-05	0.000533	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.07e-05	0.00053	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.01e-05	0.000519	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.98e-05	0.000515	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.98e-05	0.000515	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.94e-05	0.000507	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.93e-05	0.000507	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.92e-05	0.000505	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.88e-05	0.000497	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.84e-05	0.000491	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.84e-05	0.00049	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.83e-05	0.000489	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.82e-05	0.000487	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.82e-05	0.000487	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	2.81e-05	0.000486	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.79e-05	0.000482	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.79e-05	0.000481	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.78e-05	0.00048	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	2.75e-05	0.000474	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.73e-05	0.000471	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.73e-05	0.000471	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.69e-05	0.000465	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.67e-05	0.000461	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.67e-05	0.000461	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.59e-05	0.000447	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.57e-05	0.000444	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.53e-05	0.000438	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	2.51e-05	0.000433	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.48e-05	0.000429	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.48e-05	0.000428	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.44e-05	0.000422	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.4e-05	0.000415	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—VEGFA—chronic obstructive pulmonary disease	2.39e-05	0.000412	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.37e-05	0.000409	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.35e-05	0.000406	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.34e-05	0.000404	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.34e-05	0.000403	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.31e-05	0.000399	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.31e-05	0.000399	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.25e-05	0.000388	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.23e-05	0.000386	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.23e-05	0.000385	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.22e-05	0.000383	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—TGFB1—chronic obstructive pulmonary disease	2.19e-05	0.000378	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.18e-05	0.000377	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.18e-05	0.000376	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.17e-05	0.000374	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.15e-05	0.000371	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.13e-05	0.000368	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.09e-05	0.000361	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.07e-05	0.000357	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.06e-05	0.000356	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.03e-05	0.00035	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.01e-05	0.000348	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	2e-05	0.000345	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.95e-05	0.000337	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.94e-05	0.000335	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.93e-05	0.000333	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.92e-05	0.000331	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.9e-05	0.000329	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.9e-05	0.000328	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.87e-05	0.000323	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.86e-05	0.000321	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.84e-05	0.000318	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.84e-05	0.000318	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.82e-05	0.000313	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—TP53—chronic obstructive pulmonary disease	1.8e-05	0.000311	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.78e-05	0.000307	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.77e-05	0.000306	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.74e-05	0.000301	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.73e-05	0.000299	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.72e-05	0.000297	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.69e-05	0.000291	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.68e-05	0.000291	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.68e-05	0.00029	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.68e-05	0.000289	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.68e-05	0.000289	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.67e-05	0.000289	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.67e-05	0.000288	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.66e-05	0.000286	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.65e-05	0.000284	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.64e-05	0.000283	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.61e-05	0.000278	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.57e-05	0.00027	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.55e-05	0.000267	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.53e-05	0.000264	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.52e-05	0.000262	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.51e-05	0.00026	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.51e-05	0.00026	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.5e-05	0.000259	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.5e-05	0.000258	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.5e-05	0.000258	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	1.46e-05	0.000253	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.46e-05	0.000253	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ALB—chronic obstructive pulmonary disease	1.4e-05	0.000242	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.39e-05	0.00024	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.37e-05	0.000236	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.36e-05	0.000235	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.36e-05	0.000235	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—NOS3—chronic obstructive pulmonary disease	1.34e-05	0.000232	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.34e-05	0.000231	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.32e-05	0.000228	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.31e-05	0.000226	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.27e-05	0.00022	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.26e-05	0.000217	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.23e-05	0.000213	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.22e-05	0.00021	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.22e-05	0.00021	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.18e-05	0.000204	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.18e-05	0.000203	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.17e-05	0.000202	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.16e-05	0.0002	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	1.14e-05	0.000197	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.13e-05	0.000195	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.12e-05	0.000194	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.12e-05	0.000193	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.1e-05	0.00019	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	1.09e-05	0.000188	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.07e-05	0.000184	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.07e-05	0.000184	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.05e-05	0.000181	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.04e-05	0.000179	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.03e-05	0.000178	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.02e-05	0.000176	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.02e-05	0.000175	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1e-05	0.000173	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1e-05	0.000173	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.96e-06	0.000172	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.84e-06	0.00017	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.79e-06	0.000169	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.55e-06	0.000165	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.47e-06	0.000164	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.31e-06	0.000161	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.12e-06	0.000157	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.04e-06	0.000156	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.01e-06	0.000156	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.89e-06	0.000154	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.59e-06	0.000148	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—chronic obstructive pulmonary disease	8.53e-06	0.000147	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.46e-06	0.000146	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.36e-06	0.000144	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.2e-06	0.000142	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.18e-06	0.000141	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.09e-06	0.00014	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.09e-06	0.00014	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.09e-06	0.00014	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.04e-06	0.000139	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.8e-06	0.000135	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.69e-06	0.000133	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.67e-06	0.000132	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.54e-06	0.00013	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.52e-06	0.00013	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.43e-06	0.000128	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.34e-06	0.000127	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.32e-06	0.000126	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.28e-06	0.000126	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.22e-06	0.000125	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.15e-06	0.000123	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.74e-06	0.000116	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.63e-06	0.000114	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.61e-06	0.000114	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.57e-06	0.000113	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.5e-06	0.000112	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.32e-06	0.000109	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.11e-06	0.000106	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.03e-06	0.000104	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.91e-06	0.000102	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.78e-06	9.98e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.6e-06	9.66e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.55e-06	9.58e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.46e-06	9.42e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.08e-06	8.77e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5e-06	8.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.97e-06	8.57e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	4.86e-06	8.39e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	4.65e-06	8.02e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.54e-06	7.85e-05	CbGpPWpGaD
